RENAL DENERVATION FOR HYPERTENSION
Patient selection
The Symplicity™ blood pressure procedure can help a wide range of patients you see in daily clinical practice.
The right treatment for the right patients.
Consider the Symplicity™ blood pressure procedure for patients who fit one or more of the following1,2:
- Uncontrolled blood pressure (BP), despite an optimal medication regimen.
- Elevated cardiovascular risks: stroke, heart failure, diabetes, coronary heart disease, or atrial fibrillation.
- Willing to undergo a procedure.
- Unwilling or unable to adhere to medication due to side effects or intolerance.
The treatment recommended by cardiovascular experts.
A growing number of expert position papers, consensus statements, and guidelines from medical societies worldwide are shaping patient selection criteria for renal denervation, including the Symplicity™ blood pressure procedure.
ESH Guidelines recommend renal denervation as Class II for uncontrolled hypertension patients.1
Safe and effective complementary hypertension treatment option
Renal denervation, including the Symplicity™ blood pressure procedure, is recommended by the European Society of Hypertension (ESH) and endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH), as a safe and effective complementary hypertension treatment option for uncontrolled patients.1
The experts agree.
A consensus statement from the European Society of Cardiology (ESC) Council on Hypertension and European Association of Percutaneous Cardiovascular Interventions (EAPCI) recommends renal denervation as an evidence-based treatment option for uncontrolled resistant hypertension.†2
Key takeaway
We're offering an alternative and additive approach to patients who fail on lifestyle modification or on antihypertensive drugs.
— Felix Mahfoud
Why patient preference matters.
Patients with hypertension may see the Symplicity™ blood pressure procedure differently than physicians, and many may prefer a procedural approach even if they are not taking anti-hypertensive medications.3
Real-world RDN patient selection
This three-part series from Radcliffe Medical Education covers practical applications of RDN guidelines for patients with resistant hypertension. CME accredited.
Hear more from the experts on renal denervation patient selection here:
Build your HTN program.
Explore resources for introducing the Symplicity™ blood pressure procedure to your community.
Explain the risks of HTN.
Educate your patients about the risks of hypertension and why the Symplicity™ blood pressure procedure may be the right choice.
† Resistant hypertension is defined as uncontrolled office BP (≥ 140/≥ 90 mmHg), which is confirmed by out-of-office BP measurements, despite appropriate lifestyle changes and the intake of a triple-drug combination, including a diuretic at maximally tolerated doses.
1. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480.
2. Barbato E, Mahfoud F, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Cardiovascular Interventions (EAPCI). Eur J Heart. 2023;44(15):1313–1330. doi: 10.1093/eurheartj/ehad054.
3. Schmieder R, Kandzari D, Wang TD, Lee YH, Lazarus G, Pathak A. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertens. 2021;39(1):162–168. doi: 10.1097/HJH.0000000000002592.